Keytruda vs Revlimid
Side-by-side cost comparison based on Medicare Part D data
Keytruda
Pembrolizumab
Manufactured by Merck
Revlimid
Lenalidomide
Manufactured by Bristol-Myers Squibb
Revlimid costs 30% less per claim than Keytruda ($12,786.00 vs $18,176.00).
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Keytruda | Revlimid |
|---|---|---|
| Avg Cost Per Claim | $18,176.00 | $12,786.00 |
| Total Medicare Spending | $7.2B | $7.8B |
| Total Beneficiaries | 82,000 | 58,000 |
| Total Claims | 398,000 | 612,000 |
| Annual Cost/Patient | $88,220.00 | $134,914.00 |
| Year-over-Year Change | +28.6% | -3.4% |
| Generic Available | No | No |
| Patent Expiration | Jun 28, 2028 | Mar 15, 2027 |
| Manufacturer | Merck | Bristol-Myers Squibb |
| Condition | Cancer | Cancer |
| Generic Name | Pembrolizumab | Lenalidomide |
Keytruda vs Revlimid: What the Data Shows
Keytruda (Pembrolizumab) and Revlimid (Lenalidomide) are both used to treat cancer. Based on Medicare Part D data, Revlimid costs $12,786.00 per claim, which is 30% less than Keytruda at $18,176.00 per claim.
Medicare spent $7.2B on Keytruda and $7.8B on Revlimid. In terms of patient reach, Keytruda serves more beneficiaries (82,000 vs 58,000).
Year-over-year spending changed +28.6% for Keytruda and -3.4% for Revlimid. Keytruda saw significant spending growth, suggesting increased utilization or price increases.
Neither drug currently has a generic version. Keytruda patent expires Jun 28, 2028. Revlimid patent expires Mar 15, 2027.
Frequently Asked Questions
Revlimid is cheaper at $12,786.00 per claim, compared to $18,176.00 for Keytruda. That makes Revlimid about 30% less expensive per claim based on Medicare Part D data.
Yes, both Keytruda and Revlimid are used to treat cancer. Your doctor can help determine which medication is more appropriate for your specific situation.
Neither drug currently has a generic version available. Keytruda patent expires Jun 28, 2028. Revlimid patent expires Mar 15, 2027.
Medicare Part D spent $7.2B on Keytruda covering 82,000 beneficiaries, and $7.8B on Revlimid covering 58,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.